Small Cap Feast

Small Cap Feast – 19 July 2018

Dish of the Day:

No Joiners Today

Off the Menu:

No Leavers Today

What’s Cooking in the IPO Kitchen?

NEX Exchange Growth Market

Veni Vidi Vici. Investment Vehicle to identify investment opportunities and acquisitions in companies in the Precious Metals and Base Metals sectors.  Raising £490k at 50p. Market cap £0.8m. Due 8 August.


CentralNic-Schedule 1 from the business operating in proprietary retail platforms selling domain names and associated web presence services including hosting and email on a subscription basis, has acquired KeyDrive S.A  which constitutes a RTO. Raising  £24m at 52p, combined market cap of £88.7m

Trackwise—established business that manufactures specialist products using printed circuit technology. Offer TBA. Due Late July

Ovoca Gold (to be renamed Ovoca Bio PLC) – RTO of IVIX, a Russian company developing a drug candidate for the treatment of female sexual dysfunctions. No monies to be raised, market cap of £8.5m, due 30 July

Nucleus Financial—independent wrap platform provider . FYDec17 revs £40.36m and PBT of £5.1m. Offer TBA. Due late July.

Kropz PLC-Intention to float by the  emerging plant nutrient producer with an advanced stage phosphate mining project in South Africa and exploration assets in West Africa

Main Market (Standard)

Danakali—potash company focused on the development of the Colluli Potash Project in Eritrea. Currently on ASX, Mkt cap c.£108m.  Due 24 July

Main Market (Premium)

Grit Real Estate Income Group pan-African income real estate company focused on real estate investment assets in pre-selected African countries . Looking to raise net proceeds of at least $120m. To be priced at EPRA NAV of $1.43/share.  Due 31 July.

Breakfast Buffet

Hummingbird Resources (HUM.L) 31.75p £110m

First full  quarter of commercial production at Yanfolila.

33,101 ounces of gold poured at an AISC of $790/oz

Average grade of 3.43 g/t

38,726 ounces of gold sold at an average price of $1,307 per ounce

500,000 Lost Time Incident (‘LTI’) free hours achieved during the quarter

Exploration drilling campaign targeting conversion of Resources to Reserves commenced at the end of Q2

Corporate highlights at 30 June 2018

Cash of $46.2m

Net debt of $15.6m


Highlands Natural Resources (HNR.L) 22.2p £26.4m

“Highlands, the natural resources company,  announced that drilling operations at all of the additional six wells at East Denver, which are being funded entirely by its partners, have been successfully completed.

Further to the announcement on 27 June 2018, the remaining three wells, named Thunder, Hagar and Citadel, have been drilled to total depth of 17,991 ft, 17,967 ft and 18,193 ft respectively and are now cased, cemented and secured.

With the completion of the drilling operations, the pad is currently being prepared for upcoming fracking and flowback operations.  “


AO World (AO..L) 145.8p £699m

AGM Statement from the European online electrical retailer. “AO World is on track to deliver its long-term strategic plan and the Board’s expectations for the full year remain unchanged.

Overall for the quarter we are pleased to report UK revenue growth of 8% which reflects the strong start to the year, as previously reported, and a slower performance in June in our core markets impacted by weaker consumer demand.

Our Europe business has performed in line with our plan during the period, with continuing strong year-on-year revenue growth of 46.2% in constant currency (up 48.8% on a reported basis), and we continue our strategy of limited traditional marketing as planned.  We remain confident in the delivery of the plan we set out at our capital markets day in Feb 2017.”

FYMar19E rev £888m and PBT loss of £3.9m.


Carclo (CAR.L) 107.5p £78.2m

“AGM Trading Update

Trading to date in the current financial year has been in line with the Board’s expectations.

Progress in securing new Automotive lighting and medical development contracts within LED Technologies and Technical Plastics has been good and is in line with our planned timescales. The implementation of our operational improvement plans is well underway and encouraging progress has been made.”

FYMar19E PE <10x.


Green and Smart (GSH.L) 6.625p £19.6m

The “renewable energy company generating power from biogas captured through the treatment of palm oil mill effluent in Malaysia, is pleased to announce that it has raised approximately £3.2m via the subscription for 51,806,000 new common shares of no par value by Serba Dinamik International Ltd, at a price of approximately 6.19p per Subscription Share.

The net proceeds of the Subscription will be used to advance the development of the Company’s third fully-owned biogas power plant at Minyak and for working capital purposes.”

The Company also intends to publish its FY Sep 17 results and its interim results for the six months to 31 March 2018 in early August 2018. Until such time as these results are published, the Company’s Common Shares remain suspended from trading on AIM.


Amryt Pharma (AMYT.L) 17.95p £49.33m

“Amryt has had a strong H1 2018 with progress across all three pillars of its growth strategy: namely, continued revenue growth and territory expansion for its lead commercial asset Lojuxta™ (lomitapide), development of its late stage pipeline and acquiring new products to leverage its established commercial, medical and regulatory infrastructure in rare diseases. Revenues (unaudited) for the first half were €7m, representing 14% growth versus H1 2017. Cash Balance (unaudited) at 30 June 2018 was €12.2m (30 June 2017, €10.9m). Amryt is well positioned to continue to grow revenues in 2018 and the Board expects full year results to be in line with current market expectations.” “The investigational global Phase III (‘EASE’) clinical trial with AP101 for Epidermolysis bullosa (“EB”) is progressing well with a pinterim efficacy analysis expected to be completed in Q4 2018, and top-line data expected in Q2 2019.”


Tax Systems (ECV.L) 84.9p £66.6m

Hy Jun 18 update from the supplier of corporation tax software and services. “The Group has delivered a strong trading performance in the first half of the year, driven by increases in both recurring and non-recurring revenue.

Revenues for the period are expected to show a 14% increase over the comparable period in the prior year, with organic revenue growth of 9%, demonstrating the successful execution of the Company’s strategy to boost organic growth through investment in sales and pre-sales.”

The “high quality of earnings, alongside strong cash flow, has underpinned the Group’s ability to decrease its net debt by 15% to £17.5m at 30 June 2018 (31 December 2017: £20.5m; 30 June 2017: £23.6m).

EBITDA is comfortably in line with expectations and the board of directors is confident with the outlook for the full financial year. “

FYDec18E rev £16m and PBT of £5.8m.


LIDCO (LID.L) 6.5p £16.3m

“The hemodynamic monitoring company, announces it has entered into an exclusive UK distribution agreement with Maicuff Technology Ltd to take full distribution responsibilities for Maicuff’s extensive range of Non Invasive Blood Pressure (NIBP) disposable products in the UK. The three-year agreement is effective immediately.

LiDCO will introduce these products to the UK market. With increased focus on infection control, the UK market is experiencing significant growth in disposable NIBP cuffs as the market moves away from using reusable NIBP cuffs in high risk areas. LiDCO’s management estimate that the market for disposable NIBP cuffs is currently in the order of £10m per annum and growing.”


Sopheon (SPE.L) 910p £92.76m

“The international provider of software and services for complete Enterprise Innovation Management solutions, issues the following trading update for the six months to 30 June 2018.

In our Annual General Meeting announcement issued on 7 June, we noted that the positive momentum from 2017 had continued into the current year and that full year 2018 revenue visibility had risen to $23.5m compared to $17.5m the year before, an all time high. We are delighted to report that following a good close to June, revenue visibility now stands at $26.5m.

As we start the second half of the year, sales activity remains high and the board remains confident that the Company is trading comfortably in line with expectations.

With this progress, we expect revenue, EBITDA and profit before tax for the first half of 2018 to be significantly ahead of prior year performance for the corresponding period.

Net cash at 30 June 2018 stood at $15.5m, compared to $9.5m at 31 December 2017, and $6.6m at 30 June 2017.” We could see no forecasts.


Be Heard (BHRD.L) 1.265p £20.2m

HYJun18 update from the digital marketing services Group.

Group revenues in excess of £14m, +70% vs Last Year.

Like for like revenue growth of 15%.

Notable wins from Aviva, GSK, blu, and Equifax.

Be Heard converting new business as a Group alongside individual company successes.

EBITDA guidance adjusted to reflect investment in business development, service capacity and provision for client spend volatility, in the range of £3m and £3.3m on revenue of circa £29m.

Cost reductions implemented to support investment and underpin H2 2018 and 2019.

Latest industry estimates suggest an uptick in UK marketing and advertising expenditure in H2. Digital continues to drive market growth.

The Board remains confident that Be Heard is well positioned to take full advantage of the demand for integrated, end-to-end marketing services.


Head Chef:

Derren Nathan
0203 764 2344

*A corporate client of Hybridan LLP


This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email with “unsubscribe me”.